Pages

▼
Friday, November 11, 2011

Financings of the Fortnight Follows The IPO Froth

›
We're big fans of Fortune columnist Dan Primack (not pictured here). But we couldn't help notice this line in his Thursday mo...
2 comments:
Wednesday, November 09, 2011

Sanofi's Lyxumia: The Crestor to Victoza's Lipitor?

›
As Sanofi quietly filed its GLP-1 agonist Lyxumia (lixisenatide) in Europe on Nov. 3 , there came a chance to consider how this fourth-to...
Friday, November 04, 2011

Deals of the Week's Stamp Of Approval

›
FDA made a pre-emptive strike this week – perhaps a move to forestall an Occupy FDA protest? Making the most of the (political) capital i...
Thursday, November 03, 2011

With New Center, New York Aims for Genomics Leadership

›
Today, 11 of the city’s academic medical centers, along with New York City and two industry partners, Roche and Illumina, announced the...
Friday, October 28, 2011

Deals of the Week Wonders, Will Artemis Help AZ In Its Hunt for Late-Stage Pipeline?

›
It's no secret that AstraZeneca needs to bolster its late-stage pipeline. Sure, there's Brilinta, but even assuming it comes throu...

Financings of the Fortnight Tells A Tale of Two Conferences

›
Investors gauging the market mood look for signs. We also spent two days this week at the BioInvestor Forum in San Francisco looking for sig...
1 comment:
Monday, October 24, 2011

So We're Courting Biosimilars After All -- For Market Access

›
How times change. Once the evil Queen in branded biotechs' hugely profitable fairy-story, biosimilars has turned into, if not the attra...
Friday, October 21, 2011

Deals of the Week Ponders: Is IND the New Biotech Dealmaking Sweet Spot?

›
Today in the hot-off-the-presses October issue of IN VIVO we argue that early-stage biotechs ought to stop pushing their drug candidates thr...